Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a pioneering clinical-stage biotherapeutic company focused on discovering and developing Ecobiotic™ therapeutic products. These novel drugs aim to treat significant diseases by targeting the underlying biology of the human microbiome. Founded by Flagship VentureLabs, Seres is at the forefront of creating the first therapeutics that induce a shift towards health by enhancing the microbiome's biology.
The company operates primarily in the United States, leveraging its microbiome therapeutics platform to develop Ecobiotic™ microbiome therapeutics. These therapies are designed to restore health by repairing the function of a dysbiotic microbiome, particularly in the colon. Seres' lead product, SER-109, is developed to prevent the recurrence of Clostridium difficile infection (CDI), a severe infection of the colon. Additional product candidates include SER-262, SER-287, and SER-401.
Recently, Seres announced the sale of its VOWST assets to Nestlé Health Science under a non-binding memorandum of understanding. This transaction will provide Seres with capital infusions, including an upfront payment, and is expected to be completed in the next 90 days, subject to shareholder approval and other conditions. VOWST, the first FDA-approved oral microbiome therapy, prevents the recurrence of CDI in adults following antibacterial treatment for recurrent CDI.
Seres plans to use the capital from this transaction to retire its existing debt and strengthen its financial position. The company is also advancing SER-155, evaluated in a Phase 1b study in patients undergoing allogeneic hematopoietic stem cell transplantation. SER-155 has the potential to reduce gastrointestinal and related bloodstream infections, as well as acute graft-versus-host disease.
Seres Therapeutics continues to innovate in microbiome therapeutics, aiming to benefit multiple underserved patient groups, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The company's approach could protect millions of medically vulnerable patients from life-threatening infections while addressing the global public health issue of antimicrobial resistance (AMR).
Seres Therapeutics (MCRB) reported a net loss of $35.5 million in Q1 2021, an increase from $19.9 million in Q1 2020. The rise in losses stemmed from increased clinical and development expenses, totaling $29.3 million in R&D for the quarter. Despite financial losses, the company continues to progress in its clinical pipeline, with the SER-287 Phase 2b study fully enrolled and results expected mid-2021, while SER-109 shows promising outcomes from its Phase 3 study. Seres ended the quarter with $272.5 million in cash and investments.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on May 4, 2021, at 8:30 a.m. ET to discuss its Q1 2021 results and provide a business update. The call can be accessed at 844-277-9450 (domestic) and 336-525-7139 (international) using conference ID 9967338. The company is known for its microbiome therapeutics, particularly the SER-109 program, which has received FDA's Breakthrough Therapy and Orphan Drug designations for treating recurrent C. difficile infection. Its SER-287 and SER-301 programs are also advancing through clinical trials.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will have President and CEO Eric Shaff present at the Jefferies Microbiome-Based Therapeutics Summit on April 22, 2021. The presentation will be pre-recorded and accessible on Seres' website at 8:00 a.m. ET on the same day, remaining available for 21 days. Seres is known for its groundbreaking work in microbiome therapies, including the SER-109 program, which targets recurrent C. difficile infections and has received Breakthrough Therapy designation from the FDA. The company is also advancing several other therapeutic candidates for gastrointestinal diseases.
Seres Therapeutics, (Nasdaq: MCRB), announced its participation in the 31st Annual Oppenheimer Healthcare Conference on March 16 at 9:20 a.m. ET. The company will provide a corporate overview during this event.
A live audio webcast will be accessible on Seres' website, with a replay available one hour post-event for 21 days.
Seres is recognized for its innovative microbiome therapeutics, including the SER-109 program, which has received Breakthrough Therapy designation from the FDA for treating recurrent C. difficile infection.
Seres Therapeutics (Nasdaq: MCRB) announced the voluntary discontinuation of patient enrollment in the MCGRAW study, focusing on SER-401 and nivolumab for metastatic melanoma. This decision follows challenges in enrollment amidst the COVID-19 pandemic. Although the preliminary results from 10 subjects indicated that SER-401 was safe and well-tolerated, the company will deprioritize its development. Seres aims to leverage insights from this study to advance future oncology programs and continues its research in microbiome therapeutics.
Seres Therapeutics (MCRB) reported its Q4 and full year 2020 results, confirming progress in its microbiome therapeutics portfolio. Key highlights include the advancement of SER-109 towards a Biologics License Application (BLA) and achieving target enrollment for the SER-287 ECO-RESET Phase 2b study. SER-109 demonstrated an 88% sustained clinical response in a Phase 3 study for recurrent C. difficile infection, with a significant reduction in recurrence rates. The company enters 2021 with a solid financial position and a robust pipeline targeting multiple diseases.
Seres Therapeutics, Inc. (Nasdaq: MCRB) has announced the successful enrollment of 201 patients in the Phase 2b ECO-RESET clinical trial for SER-287, targeting mild-to-moderate ulcerative colitis (UC). This study aims to assess clinical remission and endoscopic improvement after treatment. The FDA has indicated that this trial may support a Biologics License Application (BLA). The company anticipates sharing topline results in mid-2021, highlighting SER-287's potential as a new therapeutic approach amidst a significant unmet need for safer UC treatments.
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced its participation in two upcoming investor conferences. The Cowen 41st Annual Health Care Conference is set for March 2, 2021, featuring a Microbiome panel discussion and 1x1 meetings. The Chardan 3rd Annual Microbiome Medicines Summit will take place on March 8, 2021, where management will present a corporate overview at 2:30 p.m. ET and conduct 1x1 meetings. An audio webcast for the Chardan presentation will be available on Seres’ website. The company is at the forefront of microbiome therapeutics, with notable programs for recurrent C. difficile infection and ulcerative colitis.
Seres Therapeutics, Inc. (Nasdaq: MCRB) will host a conference call on March 2, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 results. The company is a leader in microbiome therapeutics, focusing on multifunctional bacterial therapeutics. Notably, Seres’ SER-109 program has shown positive pivotal clinical results and received Breakthrough Therapy and Orphan Drug designations from the FDA. Additionally, SER-287 is under Phase 2b evaluation for ulcerative colitis, while other programs are in various stages of clinical trials.
Seres Therapeutics (Nasdaq: MCRB) announced new findings from its SER-109 Phase 3 ECOSPOR III clinical study related to recurrent C. difficile infection. The study demonstrated rapid engraftment of SER-109-derived bacteria in the gastrointestinal tract, achieving significant metabolic changes that create an unfavorable environment for C. difficile growth. The data revealed an 88.9% sustained clinical response rate at eight weeks post-treatment, with no serious adverse events reported. SER-109 has received FDA Breakthrough Therapy and Orphan Drug designations.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
What does Seres Therapeutics, Inc. do?
What is SER-109?
What recent transaction did Seres Therapeutics announce?
What is VOWST?
What is the financial condition of Seres Therapeutics?
Who founded Seres Therapeutics?
What other products are in Seres Therapeutics' pipeline?
What partnerships does Seres Therapeutics have?
What is the company's approach to treating diseases?
Where can I find more information about Seres Therapeutics?
